Charles Schwab Investment Management Inc. Grows Stock Position in The Chemours Company (NYSE:CC)

Charles Schwab Investment Management Inc. boosted its stake in shares of The Chemours Company (NYSE:CC - Free Report) by 6.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 1,302,272 shares of the specialty chemicals company's stock after buying an additional 73,220 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.87% of Chemours worth $22,008,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Strategic Financial Concepts LLC bought a new position in Chemours in the 4th quarter valued at $357,000. Vision One Management Partners LP bought a new position in Chemours in the 3rd quarter valued at $28,252,000. Two Sigma Advisers LP grew its position in Chemours by 9.4% in the 3rd quarter. Two Sigma Advisers LP now owns 503,100 shares of the specialty chemicals company's stock valued at $10,223,000 after acquiring an additional 43,200 shares during the last quarter. Entropy Technologies LP bought a new position in Chemours in the 4th quarter valued at $266,000. Finally, Twelve Points Wealth Management LLC grew its position in Chemours by 42.8% in the 4th quarter. Twelve Points Wealth Management LLC now owns 78,325 shares of the specialty chemicals company's stock valued at $1,324,000 after acquiring an additional 23,490 shares during the last quarter. Hedge funds and other institutional investors own 76.26% of the company's stock.

Chemours Stock Down 3.6 %

CC stock traded down $0.54 during trading on Friday, reaching $14.14. 28,509,927 shares of the company traded hands, compared to its average volume of 1,668,008. The Chemours Company has a 12 month low of $13.09 and a 12 month high of $29.21. The business has a 50 day simple moving average of $16.89 and a 200 day simple moving average of $18.33. The company has a market capitalization of $2.11 billion, a price-to-earnings ratio of 24.80 and a beta of 2.00. The company has a debt-to-equity ratio of 6.70, a quick ratio of 0.92 and a current ratio of 1.68.

Remove Ads

Chemours (NYSE:CC - Get Free Report) last issued its quarterly earnings data on Tuesday, February 18th. The specialty chemicals company reported $0.11 earnings per share for the quarter, beating analysts' consensus estimates of $0.10 by $0.01. Chemours had a return on equity of 26.54% and a net margin of 1.51%. The company had revenue of $1.36 billion for the quarter, compared to the consensus estimate of $1.37 billion. On average, equities research analysts anticipate that The Chemours Company will post 2.03 earnings per share for the current fiscal year.

Chemours Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, March 14th. Shareholders of record on Friday, February 28th were paid a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a yield of 7.07%. The ex-dividend date of this dividend was Friday, February 28th. Chemours's dividend payout ratio (DPR) is presently 175.44%.

Wall Street Analyst Weigh In

Several brokerages have commented on CC. Morgan Stanley cut their price objective on Chemours from $25.00 to $22.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. Truist Financial started coverage on Chemours in a research report on Tuesday, January 28th. They set a "buy" rating and a $27.00 price target on the stock. Royal Bank of Canada reissued an "outperform" rating and set a $25.00 price target on shares of Chemours in a research report on Thursday, December 12th. Barclays dropped their price target on Chemours from $23.00 to $19.00 and set an "equal weight" rating on the stock in a research report on Monday, February 24th. Finally, Mizuho dropped their price target on Chemours from $22.00 to $21.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 7th. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $23.11.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.